Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics reported its Q1 2024 provisional consolidated performance, recording revenue of KRW 946.9B and operating profit of KRW 221.3B, representing year-on-year increases of 31.35% and 15.41%, respectively.
📊 [Key Disclosure Details & Financial Figures]
- Reporting Period: Q1 2024 Consolidated Provisional Financial Results (Unit: KRW Million)
- Revenue: KRW 946,903M (QoQ -11.79%, YoY +31.35%)
- Operating Profit: KRW 221,299M (QoQ -36.77%, YoY +15.41%)
- Profit Before Income Tax Expenses: KRW 240,077M (QoQ -32.51%, YoY +22.08%)
- Net Profit: KRW 179,362M (QoQ -38.30%, YoY +26.53%)
- Net Profit Attributable to Owners of the Parent: KRW 179,362M (QoQ -38.30%, YoY +26.53%)
- Comparative Historical Figures:
- Previous Quarter (Q4 2023): Revenue KRW 1,073,509M / Operating Profit KRW 349,968M / Net Profit KRW 290,684M
- Same Quarter Last Year (Q1 2023): Revenue KRW 720,922M / Operating Profit KRW 191,742M / Net Profit KRW 141,755M
- Information Release Target: Domestic/foreign investors and media (Release Date: 2024-04-24)
- Other Remarks: Figures are provisional data prior to external audit completion and may be subject to change based on audit outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Audit Figures Against Periodic Financial Statements
This disclosure presents provisional consolidated operating results for Q1 2024, which remain subject to final external audit verification. Checking for any discrepancies between these preliminary figures and the final audited statements is essential to verify the accuracy and reliability of the reported financial data. Investors can confirm the finalized figures and detailed financial notes upon the release of the upcoming Q1 Quarterly Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
